- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Gain Therapeutics, Inc.: Gain Therapeutics To Present At Biotech Showcase 2025 | 2 | GlobeNewswire (USA) | ||
| 22.10. | Gain Therapeutics Regains Nasdaq Compliance | 2 | Investing.com | ||
| 21.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 | 1 | GlobeNewswire (USA) | ||
| 03.10. | Gain Therapeutics, Inc.: Gain Therapeutics to Participate at Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 01.10. | Gain Therapeutics shares hold buy rating after presentation | 1 | Investing.com | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.10. | Gain Therapeutics-Aktien behalten Kaufempfehlung nach Präsentation | 1 | Investing.com Deutsch | ||
| 30.09. | BTIG maintains Buy rating on Gain Therapeutics shares | 1 | Investing.com | ||
| 30.09. | BTIG hält an Kaufempfehlung für Gain Therapeutics-Aktien fest | 1 | Investing.com Deutsch | ||
| 30.09. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers | 71 | GlobeNewswire (Europe) | GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Gain... ► Artikel lesen | |
| 26.09. | Gain Therapeutics, Inc.: Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease | 3 | GlobeNewswire (USA) | ||
| 19.09. | Gain Therapeutics, Inc.: Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024 | 1 | GlobeNewswire (USA) | ||
| 19.09. | Gain Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.09. | Gain Therapeutics Initiates $50 million equity distribution | 1 | Investing.com | ||
| 06.09. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.09. | Gain Therapeutics shares hold steady as analyst maintains buy rating | 1 | Investing.com | ||
| 29.08. | Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease | 2 | Benzinga.com | ||
| 29.08. | Gain Therapeutics' GT-02287 For Parkinson's Disease Shows Positive Results In Phase 1 Clinical Trial | - | RTTNews | ||
| 29.08. | Gain Therapeutics reports positive Phase 1 results for Parkinson's drug | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,895 | -2,85 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,260 | -15,44 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+1,27 %) liegt der Kurs bei 1,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.
